Targeted drug plus focused radiation for EGFR-positive cancer that has spread a little
Treatments studied
Part of Cancer clinical trials.
This study tests a new targeted drug (MRG003) combined with precise radiation (SBRT) for people with EGFR-positive solid tumors that have spread to a few new spots. The goal is to see if this combination works better than standard treatments to control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer has come back or spread to 5 or fewer spots (oligometastases) that can be treated with focused radiation (SBRT).
- Your original tumor has been treated and is under control.
- You have a tumor sample that tested positive for EGFR protein.
- You are in good overall health (ECOG score 0 or 1) and expected to live at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called MRG003 for people with certain advanced cancers that have a specific protein, EGFR. The drug targets the cancer cells that have this protein, which may help stop the cancer from growing.
This trial tests an investigational drug called MRG003 added to your current treatment for advanced thyroid cancer that has stopped responding. It may help people with specific types of thyroid cancer and certain tumor markers.
This study tests a new cancer drug called Becotatug Vedotin in children ages 2–18 with certain types of solid tumors (cancers that form in organs or tissues) that have an EGFR protein. The drug is designed to find tumors with this protein and attack cancer cells while sparing healthy ones.
This trial tests a new targeted drug (cetuximab β) combined with radiation and chemotherapy for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of a targeted pill (befotertinib) and radiation for people with stage IV non-small cell lung cancer that has an EGFR mutation and has spread to only a few spots. The study uses a blood test to guide treatment and aims to see if this combination can help control the cancer better.
This trial tests whether adding radiation therapy to a drug combination can help people with a specific type of lung cancer that has stopped responding to standard first-line pills. It's for patients whose cancer has a certain gene change (EGFR) and has spread to other parts of the body.
Hear when a new Oligo-metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.